LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences
02 November 2021 - 10:00PM
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage
biotechnology company focused on developing its proprietary
Gammabody™ platform of bispecific gamma delta T cell engagers
(bsTCEs) to transform the treatment of cancer, today announced that
Paul W.H.I. Parren, Ph.D., executive vice president, head of
research and development (R&D) at LAVA, will participate in
three upcoming scientific conferences in November.
“Gamma delta T cells provide a highly promising
effector cell modality,” said Paul W.H.I. Parren, Ph.D., executive
vice president, head of R&D at LAVA. “I look forward to sharing
data on several bispecific gamma delta T cell engagers derived from
our Gammabody™ platform that pair potent and selective tumor cell
killing with a low toxicity risk profile, thereby potentially
translating into a wider therapeutic window. Our Gammabody™
platform provides a novel immuno-oncology approach to fight
cancer.”
Details of Dr. Parren’s upcoming conference
participation are as follows:
13th
Annual PEGS Europe Protein & Antibody Engineering
Summit,
Nov. 2-4,
2021, Barcelona &
VirtualSession Chair: Progress with Gamma
Delta T Cell TherapiesSession Date/Time: Wed.,
Nov. 3, 2021 at 11:35 CET
European Antibody Congress Festival of
Biologics,
Nov. 9-11,
2021, Basel, Switzerland
Keynote Panel Discussion: Next generation antibody
therapeutics: discovery, development and beyondPanel
Discussion Date/Time: Tues., Nov. 9, 2021 at 10:00 CET
Presentation: Bispecifics &
Multispecifics Track – Bispecific gamma-delta T cell
engagersPresentation Date/Time: Tues., Nov. 9, 2021 at 14:00
CET
Session Chair: Bispecifics
& Multispecifics TrackSession Date/Time:
Tues., Nov. 9, 2021 at 15:40 CET
The Biotech Pharma
Summit,
Nov. 29-30,
2021, Porto, Portugal
& VirtualVirtual
Presentation: Bispecific γδ T Cell Engagers for the
Treatment of CancerVirtual Presentation Date/Time:
Tues., Nov. 30, 2021 at 14:30 GMT
About LAVA TherapeuticsLAVA
Therapeutics N.V. is a clinical-stage biotechnology company
utilizing its proprietary Gammabody™ platform to develop a
portfolio of bispecific gamma delta T cell engagers (gamma delta
bsTCEs) for the treatment of solid tumors and hematological
malignancies. The company’s innovative approach utilizes bispecific
antibodies engineered to selectively kill cancer cells via the
triggering of Vγ9Vδ2 T cell antitumor effector functions upon
cross-linking to tumor associated antigens. A Phase 1/2a clinical
study evaluating LAVA-051 in patients with certain hematological
malignancies is enrolling patients (NCT04887259). The company
currently anticipates data from the Phase 1 dose escalation phase
of the study in the first half of 2022 with top line clinical data
from the Phase 2a expansion cohorts expected in the second half of
2022. The company plans to initiate a Phase 1/2a clinical study to
evaluate LAVA-1207 in patients with prostate cancer in the fourth
quarter of 2021. For more information, please visit
www.lavatherapeutics.com and follow us on LinkedIn and Twitter.
LAVA’s Cautionary Note on
Forward-Looking StatementsThis press release contains
forward-looking statements, including in respect of the company’s
anticipated growth and clinical developments plans, including the
timing of clinical trials. Words such as “anticipate,” “believe,”
“could,” “will,” “may,” “expect,” “should,” “plan,” “intend,”
“estimate,” “potential” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on LAVA’s expectations
and assumptions as of the date of this press release and are
subject to various risks and uncertainties that may cause actual
results to differ materially from these forward-looking statements.
Forward-looking statements contained in this press release include,
but are not limited to, statements about the preclinical data,
clinical development and scope of clinical trials, and the
potential use of our product candidates to treat various tumor
targets. Many factors, risks and uncertainties may cause
differences between current expectations and actual results
including, among other things, the timing and results of our
research and development programs and preclinical and clinical
trials, our ability to obtain regulatory approval for and
commercialize our product candidates, our ability to leverage our
initial programs to develop additional product candidates using our
GammabodyTM platform, and the failure of LAVA’s collaborators to
support or advance collaborations or our product candidates. In
addition, the COVID-19 pandemic may disrupt our business and that
of the third parties on which we depend, including delaying or
otherwise disrupting our clinical trials and preclinical studies,
manufacturing and supply chain, or impairing employee productivity.
LAVA assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
CONTACTCatherine
Day+1-917-763-2709catherine@newdaybioconsulting.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2023 to Apr 2024